Assignee
MEDIGENE IMMUNOTHERAPIES GMBH
DE·12 granted patents·12 pending applications·11 citations·filing 2016–2025
Top patents by PatentIndex Score
24 records- 0186US10882891B2Dendritic cell compositionMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2016·Granted Jan 5, 2021·4 cites·15 claims
- 0284US11292838B2Method for generating antibodies against T cell receptorMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2016·Granted Apr 5, 2022·6 cites·17 claims
- 0375US2024417440A1Nyeso tcrMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2024·Application pending·0 cites
- 0474US12344654B2Mage A4 T cell receptorsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2020·Granted Jul 1, 2025·1 cites·26 claims
- 0571US12103957B2Nyeso tcrMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2022·Granted Oct 1, 2024·0 cites·20 claims
- 0669US2024083967A1T cell receptors and uses thereofMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2023·Application pending·0 cites
- 0767US2026055159A1Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptorsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2023·Application pending·0 cites
- 0862US11267864B2Nyeso tcrMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2019·Granted Mar 8, 2022·0 cites·18 claims
- 0962US2025346648A1Mage a4 t cell receptorsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2025·Application pending·0 cites
- 1061US2024374729A1Combination of antigen specific t cell receptors and chimeric co-stimulatory receptorsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2022·Application pending·0 cites
- 1158US11732020B2T cell receptors and uses thereofMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2017·Granted Aug 22, 2023·0 cites·13 claims
- 1255US11155589B2Generation of antigen-specific TCRsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2016·Granted Oct 26, 2021·0 cites·20 claims
- 1352US2023340064A1Mage-a3 specific t cell receptors and their useMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2021·Application pending·0 cites
- 1452US2023340065A1Prame specific t-cell receptors and uses thereofMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2021·Application pending·0 cites
- 1550US2023133564A1Cd3-fusion protein and uses thereofMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2021·Application pending·0 cites
- 1650US2024277762A1Combination of prame specific t cell receptors and chimeric co-stimulatory receptorsMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2022·Application pending·0 cites
- 1748US12173318B2Enrichment of T cells using an anti-Cß antibodyMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2021·Granted Dec 24, 2024·0 cites·16 claims
- 1846US2021063413A1Dendritic cell potency assayMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2017·Application pending·0 cites
- 1943US12331095B2Inducible T cell receptors and uses thereofMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2019·Granted Jun 17, 2025·0 cites·19 claims
- 2041US12240883B2MAGEA1 specific T cell receptors and their useMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2020·Granted Mar 4, 2025·0 cites·9 claims
- 2141US2022251235A1Magea10 specific t cell receptors and their useMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2020·Application pending·0 cites
- 2240US12195515B2HA-1 specific T cell receptors and their useMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2019·Granted Jan 14, 2025·0 cites·8 claims
- 2339US10858760B2T cell receptor libraryMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2016·Granted Dec 8, 2020·0 cites·17 claims
- 2437US2018256716A1T-cell receptor specific antibodiesMEDIGENE IMMUNOTHERAPIES GMBH·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when MEDIGENE IMMUNOTHERAPIES GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →